Tenaya Therapeutics (TNYA) Other Non-Current Liabilities (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Other Non-Current Liabilities of $418000.0 for Q1 2026, up 45.64% year-over-year from $287000.0 in Q1 2025, and up 1.95% quarter-over-quarter from $410000.0 in Q4 2025.
Tenaya Therapeutics (TNYA) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $418000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 45.64% year-over-year to $418000.0; the TTM figure through Mar 2026 stood at $418000.0 (up 45.64% YoY), while the FY2025 annual figure was $410000.0, up 45.91% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $418000.0, up from $410000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $418000.0 in Q1 2026, with the low at $212000.0 in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $259000.0 (2024), against an average of $273176.5.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities soared 7133.33% in 2022, then advanced 9.06% in 2025.
- Tenaya Therapeutics' Other Non-Current Liabilities stood at $228000.0 in 2022, then grew by 10.96% to $253000.0 in 2023, then advanced by 11.07% to $281000.0 in 2024, then surged by 45.91% to $410000.0 in 2025, then grew by 1.95% to $418000.0 in 2026.
- Business Quant data shows TNYA's Other Non-Current Liabilities at $418000.0 in Q1 2026, $410000.0 in Q4 2025, and $301000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103,000.00 |
| Mar 31, 2026 | 418,000.00 |
| Dec 31, 2025 | 410,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 287,000.00 |
| Dec 31, 2024 | 281,000.00 |
| Sep 30, 2024 | 276,000.00 |
| Jun 30, 2024 | 266,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Dec 31, 2023 | 253,000.00 |
| Sep 30, 2023 | 246,000.00 |
| Jun 30, 2023 | 240,000.00 |
| Mar 31, 2023 | 234,000.00 |
| Dec 31, 2022 | 228,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Jun 30, 2022 | 217,000.00 |
| Mar 31, 2022 | 212,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 96,000.00 |